Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m; Revenue Growth of 16.7% YoY with an EBITDA Margin of 20%.
DailyMirror.News,India, July 29, 2024: Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q1FY25)